Janssen Announces U.S. FDA Breakthrough Therapy Designation for Investigational Prophylactic Vaccine for the Prevention of Respiratory Syncytial Virus in Older Adults

LEIDEN, Netherlands– September 3, 2019– The Janssen Pharmaceutical Companies of Johnson& Johnson (Janssen) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for the...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials